| Literature DB >> 28620715 |
Horacio Kaufmann1, Jose-Alberto Palma2.
Abstract
Entities:
Mesh:
Year: 2017 PMID: 28620715 PMCID: PMC5524853 DOI: 10.1007/s10286-017-0437-3
Source DB: PubMed Journal: Clin Auton Res ISSN: 0959-9851 Impact factor: 4.435
Characteristics of neurogenic and non-neurogenic orthostatic hypotension
Modified from [4]
| Non-neurogenic orthostatic hypotension | Neurogenic orthostatic hypotension | |
|---|---|---|
| Frequency | Frequent (particularly in the elderly) | Rare (<200,000 in the US) |
| Onset | Variable | Chronic in synucleinopathies. Acute or sub-acute in immune-mediated neuropathies and ganglionopathies |
| Causes | Intravascular volume loss (e.g., dehydration, anemia) | Defective norepinephrine release from sympathetic post-ganglionic neurons upon standing up |
| Prognosis | Resolves when underlying cause is corrected | Chronic disorder |
| Increase in heart rate upon standing | Pronounced (usually >25 bpm) | Mild or absent (usually <20 bpm) |
| Blood pressure overshoot (phase 4) in Valsalva maneuver | Present | Absent |
| Increase in plasma norepinephrine levels upon standing | Normal or enhanced (at least ×2) | Reduced or absent (less than ×2) |
| Other symptoms of autonomic failure | No | Constipation |
| Concomitant neurological deficits | None (or if present, they are not related to OH) | None |
Fig. 1Blood pressure and cerebral blood flow in a patient with neurogenic orthostatic hypotension [4]. The upper tracing displays blood flow velocity as measured by transcranial Doppler ultrasound of the middle cerebral artery (MCA), which is proportional to cerebral blood flow. The lower tracing shows continuous blood pressure recorded with plethysmography. When the patient is in the supine position, BP is normal (120/85 mmHg) and MCA velocity (Vm) is 55 cm/s, indicating normal cerebral blood flow. When the patient stands up, BP drops rapidly to 68/55 mmHg and cerebral blood flow falls by nearly 50% as shown by Vm down to 28 cm/s. The patient becomes symptomatic, feels faint and is unable to remain standing (indicated by a swirl). The patient then sits down and his BP increases to 95/62 mmHg. Although this BP value is still low, the patient is not symptomatic because Vm increased to 46 cm/s, indicating almost normal cerebral blood flow. This tracing shows that for a patient to become asymptomatic, BP does not have to return to normal values but only to increase above the lower limit of cerebral autoregulation
Fig. 2Typical 24-h ambulatory blood pressure (BP) monitoring results in a patient with neurogenic OH and supine hypertension. The orange dashed horizontal red denotes the limit for hyper- or hypotension. There is a significant drop in BP (systolic BP <90 mmHg) after breakfast, lunch and dinner (arrows). According to this patient’s diary, lunch consisted of a slice of cheese pizza with French fries and a piece of cheesecake, all accompanied by a glass of wine. This is consistent with postprandial hypotension. The patient also had nocturnal hypertension (up to systolic BP of 180 mmHg) while sleeping in the supine position, and one episode of hypotension (while he was in the standing position in the bathroom urinating). Upon awakening the next morning, his orthostatic hypotension is worse due to volume depletion overnight. This recording emphasizes the need to sleep with the head of the bed raised 30°–45° and to avoid high-calorie meals and alcohol during daytime
Fig. 3Treatment algorithm in patients with neurogenic orthostatic hypotension. Modified from [4]. Removal of aggravating factors and initiation of non-pharmacological measures must always predate pharmacological agents
Recommendations of non-pharmacologic treatments for neurogenic orthostatic hypotension
Reproduced from [1]
| Treatment | Notes |
|---|---|
| Educate patients and their caregivers | Includes education on understanding orthostatic intolerance; avoiding prolonged standing, immobilization, or prolonged diurnal recumbence; as well as rising gradually from supine and sitting positions, especially in the morning, after meals, and after urination/defecation |
| Change diet | Eat smaller, rather than large, and more frequent meals. With nOH, sympathetic vasoconstrictor nerve activity is deficient and many patients become severely hypotensive within 2 h of eating. In patients with postprandial hypotension, smaller and more frequent meals are recommended |
| Avoid increased core body temperature | Elevation in body temperature causes peripheral vasodilation. Patients with nOH should avoid situations that could increase core body temperature, such as excessive high-intensity exercise; exercise when ambient temperature and humidity are high; utilization of hot-tubs, spas, or saunas; prolonged hot showers, etc. |
| Avoidance of physical deconditioning | Lower body strength training and moderate, non-strenuous activities may be incorporated into standard treatment for patients with nOH |
| Use head-up position while sleeping | Use of head of the bed elevation up to 30 degrees during sleep. This may reduce nocturia, volume depletion, and supine hypertension |
| Increase hydration | Increased fluid intake, including rapid water bolus intake if needed, can potentially combat acute nOH symptoms. Volume expansion requires up to 64 oz of water daily. Proper hydration can produce both acute and long-lasting significant clinical benefits to patients with nOH |
| Increase salt intake | For the patient with nOH, it is recommended that they add up to 1–2 teaspoons (2.3–4.6 g) of salt per day to their normal diet. However, increasing salt intake should be used with caution in patients with heart and kidney failure |
| Use compression garments | These provide a reduction of peripheral pooling in the lower limbs and splanchnic region. Compression of 30–40 mmHg is required to improve venous return and provide a meaningful blood pressure impact. Abdominal binders offer an effective alternative |
| Treat anemia and vitamin deficiencies | Anemia leads to decreased blood viscosity and oxygen-carrying capacity and may worsen symptoms of nOH. Vitamin B12 deficiency (<250 pg/mL with elevated methylmalonic acid levels) may also unmask or exacerbate symptoms of nOH |
Fig. 4The vicious cycle of physical deconditioning. Modified from [4]. Because patients with neurogenic orthostatic hypotension (nOH) have intolerable symptoms when standing they avoid moving; lack of physical activity results in striated and cardiac muscle atrophy, which further impairs cardiovascular control. This, in turn, further increases the orthostatic fall in blood pressure, worsening symptoms in a perpetual cycle. Improving symptoms can break this cycle
Pharmacologic treatments for neurogenic orthostatic hypotension
Modified from [1]
| Treatment | Recommended dosing regimen | Drug class and notes | Safety notes |
|---|---|---|---|
| FDA-approved for the treatment of symptomatic neurogenic OH | |||
| Droxidopa | 100–600 mg three times/day (dosed morning, midday, and 3–4 h prior to bedtime) or tailored to each patients’ needs | Pro-drug of norepinephrine | Supine hypertension, headache, dizziness, nausea, and fatigue; caution in congestive heart failure and chronic renal failure |
| Midodrine | 2.5–15 mg twice or three times/day (dosed morning, midday, and 3–4 h prior to bedtime) | Direct alpha1-adrenoreceptor agonist | Supine hypertension, piloerection, scalp itching, and urinary retention; caution in congestive heart failure and chronic renal failure |
| Not specifically FDA-approved for neurogenic OH | |||
| Fludrocortisone | 0.1–0.2 mg/day; little benefit from observed dose beyond 0.2 mg/day | Synthetic mineralocorticoid. | Supine hypertension, hypokalemia, renal failure, and edema; caution in congestive heart failure |
| Pyridostigmine | 30–60 mg twice or three times/day | Acetylcholinesterase inhibitor. Marginal efficacy in nOH | Abdominal cramps, diarrhea, sialorrhea, excessive sweating, urinary incontinence |
Pharmacological treatments for supine hypertension associated with neurogenic orthostatic hypotension
Modified from [1]
| Treatment optionsa | Typical dose |
|---|---|
| Captopril | 25 mg at bedtime |
| Clonidineb | 0.1 mg with dinner |
| Hydralazine | 10–25 mg at bedtime |
| Losartan | 50 mg at bedtime |
| Nitroglycerine patch | 0.1 mg/h patch at bedtime (remove patch in the morning) |
No controlled trials have been performed. The risk–benefit ratio should be individually assessed
aShort-acting antihypertensives should be administered at bedtime only, not during daytime hours. Many medications have twice or three times/day as recommended dosing and patients may inadvertently start taking these medications during daytime hours and worsen symptoms of nOH
bThe use of clonidine carries a risk of a severe hypotension in the morning as well as rebound hypertension